Advisory Panel Members Respond To Wood Editorial In NEJM On Plan B
This article was originally published in The Tan Sheet
An evaluation of package information for over-the-counter levonorgestrel needs to include typical-use and not just optimal-use rates, according to a letter to the editor in the June 3 New England Journal of Medicine signed by members of FDA's Reproductive Health Drugs Advisory Committee
You may also be interested in...
Barr Labs will continue to work with FDA toward approval of emergency contraceptive Plan B (levonorgestrel .75 mg) for OTC use, the company said in a May 6 statement
FDA's review of an Rx-to-OTC switch for the Plan B emergency contraceptive should not involve consideration of age restrictions on use, according to Alastair Wood, MD, Vanderbilt University Medical Center
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC